Vertex Pharmaceuticals (VRTX) EBT (2009 - 2026)

Vertex Pharmaceuticals has reported EBT for 18 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 71.54% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $5.2 billion (up 1820.75% YoY), and the FY2025 full-year result was $4.6 billion, up 1768.49% from the prior year.
• EBT for Q1 2026 stood at $1.3 billion, down from $1.3 billion in the prior quarter.
• The five-year high for EBT was $1.3 billion in Q4 2025, with the low at -$3.4 billion in Q2 2024.
• Average EBT over 5 years is $868.0 million, with a median of $1.2 billion recorded in 2023.
• Year-over-year, EBT jumped 2417.65% in 2022 and slumped 391.97% in 2024.
• Tracing VRTX's EBT over 5 years: stood at $1.1 billion in 2022, then increased by 6.58% to $1.1 billion in 2023, then dropped by 0.97% to $1.1 billion in 2024, then advanced by 17.11% to $1.3 billion in 2025, then fell by 5.87% to $1.3 billion in 2026.
• The last three EBT figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison